GenFleet Therapeutics (HKG:2595) said Tuesday it presented the updated Phase 2 data for GFH375 monotherapy in pretreated KRAS G12D-mutant non-small cell lung cancer at the World Conference on Lung Cancer in South Korea.
The company said the updated results showed an objective response rate of 59.2%, a disease control rate of 93%, and a 12-month overall survival rate of 77% in 71 subjects who received 600 milligrams of the oral drug, according to a Tuesday disclosure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.